Chunghwa Chemical Synthesis & Biotech Co Ltd 1762
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NT$34.35
- Day Range
- NT$33.45–34.35
- 52-Week Range
- NT$24.20–44.75
- Bid/Ask
- NT$33.50 / NT$33.60
- Shares Outstanding
- 76.92M
- Market Cap
- NT$2.58B
- Volume/Avg
- 124,000 / 130,237
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 243
- Website
- http://www.ccsb.com.tw
Valuation
|
Metric
|
1762
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.81 |
Price/Sales | 2.00 |
Price/Cash Flow | 22.66 |
Price/Earnings
1762
Financial Strength
|
Metric
|
1762
|
|---|---|
Quick Ratio | 1.77 |
Current Ratio | 4.06 |
Interest Coverage | −1.34 |
Quick Ratio
1762
Profitability
|
Metric
|
1762
|
|---|---|
Return on Assets (Normalized) | −1.08% |
Return on Equity (Normalized) | −1.50% |
Return on Invested Capital (Normalized) | −0.95% |
Return on Assets
1762
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%H<!nS | LOCK|S@Z? | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|k>!?Qnk | LOCK|GJZnn | $83B | |||
| Moderna Inc
MRNA
| LOCK|!vBtsN | LOCK|p< | $80B | |||
| argenx SE ADR
ARGX
| LOCK|ZfQ$f%? | LOCK|Qx | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|frb<Nf | LOCK|gyx | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|l$%FdM | LOCK|n<$% | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|zHK$Yx@S | LOCK|#G%z | $28B | |||
| Incyte Corp
INCY
| LOCK|?DyNV&v | LOCK|!% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&Qv!W? | LOCK|PF! | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%zDcbm^ | LOCK|#y@ | $14B |
United States